Clinical pharmacology of old and new antiarrhythmic drugs

S. Nattel, D. P. Zipes

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The goal of this chapter is to provide information that will aid the physician in the safe and effective use of drug therapy for patients with arrhythmias. Prior to beginning drug therapy, the physician must determine its need by evaluating the nature of the arrhythmia, its severity, and the risks it presents, as well as by excluding reversible disorders such as electrolyte imbalance (hypokalemia and hypomagnesemia), acid-base abnormalities, heart failure, hypoxia, drug toxicity (digitalis, bronchodilators, tricyclic antidepressants, phenothiazines), thyrotoxicosis, and pulmonary disease which can cause or contribute to the development of cardiac arrhythmias. One major feature common to most antiarrhythmic agents is a narrow toxic/therapeutic index. Thus, potentially life-threatening complications of therapy may result from amounts of drug that only slightly exceed the amount necessary to produce beneficial effects. Because subtherapeutic doses of a drug may also be dangerous, by permitting development of a serious arrhythmia, careful dosing with these agents is essential. In order to maintain adequate but nontoxic amounts of drug in the body, one must understand the factors determining drug distribution and elimination.

Original languageEnglish
Pages (from-to)221-248
Number of pages28
JournalCardiovascular Clinics
Volume11
Issue number1
StatePublished - 1980

Fingerprint

Clinical Pharmacology
Anti-Arrhythmia Agents
Cardiac Arrhythmias
Pharmaceutical Preparations
Phenothiazines
Physicians
Drug Therapy
Thyrotoxicosis
Hypokalemia
Digitalis
Tricyclic Antidepressive Agents
Poisons
Bronchodilator Agents
Drug-Related Side Effects and Adverse Reactions
Electrolytes
Lung Diseases
Heart Failure
Acids
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Nattel, S., & Zipes, D. P. (1980). Clinical pharmacology of old and new antiarrhythmic drugs. Cardiovascular Clinics, 11(1), 221-248.

Clinical pharmacology of old and new antiarrhythmic drugs. / Nattel, S.; Zipes, D. P.

In: Cardiovascular Clinics, Vol. 11, No. 1, 1980, p. 221-248.

Research output: Contribution to journalArticle

Nattel, S & Zipes, DP 1980, 'Clinical pharmacology of old and new antiarrhythmic drugs', Cardiovascular Clinics, vol. 11, no. 1, pp. 221-248.
Nattel, S. ; Zipes, D. P. / Clinical pharmacology of old and new antiarrhythmic drugs. In: Cardiovascular Clinics. 1980 ; Vol. 11, No. 1. pp. 221-248.
@article{f592c11f28e5463584c2089256675fc8,
title = "Clinical pharmacology of old and new antiarrhythmic drugs",
abstract = "The goal of this chapter is to provide information that will aid the physician in the safe and effective use of drug therapy for patients with arrhythmias. Prior to beginning drug therapy, the physician must determine its need by evaluating the nature of the arrhythmia, its severity, and the risks it presents, as well as by excluding reversible disorders such as electrolyte imbalance (hypokalemia and hypomagnesemia), acid-base abnormalities, heart failure, hypoxia, drug toxicity (digitalis, bronchodilators, tricyclic antidepressants, phenothiazines), thyrotoxicosis, and pulmonary disease which can cause or contribute to the development of cardiac arrhythmias. One major feature common to most antiarrhythmic agents is a narrow toxic/therapeutic index. Thus, potentially life-threatening complications of therapy may result from amounts of drug that only slightly exceed the amount necessary to produce beneficial effects. Because subtherapeutic doses of a drug may also be dangerous, by permitting development of a serious arrhythmia, careful dosing with these agents is essential. In order to maintain adequate but nontoxic amounts of drug in the body, one must understand the factors determining drug distribution and elimination.",
author = "S. Nattel and Zipes, {D. P.}",
year = "1980",
language = "English",
volume = "11",
pages = "221--248",
journal = "Cardiovascular Clinics",
issn = "0069-0384",
number = "1",

}

TY - JOUR

T1 - Clinical pharmacology of old and new antiarrhythmic drugs

AU - Nattel, S.

AU - Zipes, D. P.

PY - 1980

Y1 - 1980

N2 - The goal of this chapter is to provide information that will aid the physician in the safe and effective use of drug therapy for patients with arrhythmias. Prior to beginning drug therapy, the physician must determine its need by evaluating the nature of the arrhythmia, its severity, and the risks it presents, as well as by excluding reversible disorders such as electrolyte imbalance (hypokalemia and hypomagnesemia), acid-base abnormalities, heart failure, hypoxia, drug toxicity (digitalis, bronchodilators, tricyclic antidepressants, phenothiazines), thyrotoxicosis, and pulmonary disease which can cause or contribute to the development of cardiac arrhythmias. One major feature common to most antiarrhythmic agents is a narrow toxic/therapeutic index. Thus, potentially life-threatening complications of therapy may result from amounts of drug that only slightly exceed the amount necessary to produce beneficial effects. Because subtherapeutic doses of a drug may also be dangerous, by permitting development of a serious arrhythmia, careful dosing with these agents is essential. In order to maintain adequate but nontoxic amounts of drug in the body, one must understand the factors determining drug distribution and elimination.

AB - The goal of this chapter is to provide information that will aid the physician in the safe and effective use of drug therapy for patients with arrhythmias. Prior to beginning drug therapy, the physician must determine its need by evaluating the nature of the arrhythmia, its severity, and the risks it presents, as well as by excluding reversible disorders such as electrolyte imbalance (hypokalemia and hypomagnesemia), acid-base abnormalities, heart failure, hypoxia, drug toxicity (digitalis, bronchodilators, tricyclic antidepressants, phenothiazines), thyrotoxicosis, and pulmonary disease which can cause or contribute to the development of cardiac arrhythmias. One major feature common to most antiarrhythmic agents is a narrow toxic/therapeutic index. Thus, potentially life-threatening complications of therapy may result from amounts of drug that only slightly exceed the amount necessary to produce beneficial effects. Because subtherapeutic doses of a drug may also be dangerous, by permitting development of a serious arrhythmia, careful dosing with these agents is essential. In order to maintain adequate but nontoxic amounts of drug in the body, one must understand the factors determining drug distribution and elimination.

UR - http://www.scopus.com/inward/record.url?scp=0019209485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019209485&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 221

EP - 248

JO - Cardiovascular Clinics

JF - Cardiovascular Clinics

SN - 0069-0384

IS - 1

ER -